China fills vaccine gap left by US, India with expanded production to reach 5b doses annually
Global Times reporter on society, cybersecurity, diplomatic relations and topics related to Xinjiang.
Liu Caiyu and Leng Shumei Published: May 10, 2021 10:13 PM Updated: May 11, 2021 10:18 AM
A nurse shows a vial of the Sinopharm vaccine at the Panadura Health Office in Kalutara District, in the outskirts of capital Colombo, Sri Lanka, on May 8, 2021. Sri Lanka's Health Ministry on Saturday began administering the Sinopharm vaccine to local nationals, soon after the World Health Organization (WHO) approved it for emergency use worldwide.(Photo: Xinhua)
The grave epidemic situation in India, the world's largest vaccine producer, the WHO's approval of Chinese vaccines for emergency use, lingering questions on whether the US can really deliver its promise to provide vaccines to the world, all these have led to a widely acknowledged situation that China could be a much more reliable global vaccine supplier, especially as domestic vaccine producers vowed to ramp up production to meet domestic immunity targets and overseas demand.